Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ABBV-324

Antibody-drug conjugate · Kills target cells, directed at glypican 3 (GPC3) · developed by AbbVie

Phase 1 Most advanced trial

ABBV Developer

1 Registered trials

What is ABBV-324?

ABBV-324 is an antibody-drug conjugate targeting glypican 3 (GPC3), a tumor-associated antigen overexpressed in various cancers. The antibody binds GPC3 on tumor cells, and upon internalization, releases a cytotoxic payload that kills GPC3-expressing cancer cells. It is studied in hepatocellular cancer and squamous-cell non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Antibody-drug conjugate
Targets: glypican 3 (GPC3)
Mechanism: Kills target cells, directed at glypican 3 (GPC3)
Pathways: cell_division, growth_regulation
Therapy area: Oncology
Developer: AbbVie (ABBV)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06858813	Phase 1	Hepatocellular Cancer	Recruiting	ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatocellular CancerSquamous-Cell Non-Small Cell Lung Cancer

Other drugs acting on GPC3

ZW251 Phase 1

More from AbbVie

Adalimumab FDA approved Atogepant FDA approved Pivekimab Sunirine FDA approved Risankizumab FDA approved Telisotuzumab Vedotin FDA approved Upadacitinib FDA approved Venetoclax FDA approved ABBV-1042 Phase 1 ABBV-291 Phase 1 ABBV-295 Phase 2 ABBV-313 Phase 1 ABBV-438 Phase 1

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind ABBV-324

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z